Meihua received the Shanghai Stock Exchange inquiry letter announcement

on the afternoon of May 24, 2016, Meihua Biotech Group Co., Ltd(the "Company") received a letter of inquiry from the listed company of the Shanghai Stock Exchange on matters relating to the termination of the planning of the issuance of shares to purchase assets by Meihua Biotech Group Co., Ltd(SSE No63s
The full text of the letter reads as follows:63sOn December 24, 2015, your company suspended trading to announce the planning of the issuance of shares to purchase assets ("this reorganization")On May 24, 2016, your company announced that it had terminated this reorganization because it had failed to reach agreement with the counterparty on such matters as competition, performance commitment, etcThe restructuring is planning a suspension of trading time of up to 5 months, the investor's trading rights have a greater impactThe Company is requested to supplement the verification of the following matters and to make public disclosure:63s, the relevant rules of the listed company's material asset restructuring, such as inter-industry competition, performance commitment compensation and other issues have clear63sPlease indicate the reasons why, after a long suspension of trading, no agreement has been reached with the counterparty on the above issues, and whether the financial advisor has fulfilled the relevant reminder obligations in a diligent and responsible nature63s
2The company plans to suspend trading for this reorganization for up to 5 months, during which the suspension of trading for overseas acquisitions and other complex reasons repeatedly applied for extension of the re-listing, but the relevant restructuring progress announcement never revealed the above-mentioned risk stakes that may lead to the termination of the reorganization, please the company in conjunction with the reorganization transaction process memorandum, explain the failure to disclose the above-mentioned restructuring may be able to terminate the risk of reason63s
3According to the announcement, the company and its controlling shareholders reserve the right to pursue the legal liability of The first sugar of Hijie63s
Please specify the measures that the company intends to take to safeguard its legitimate rights and interests in the context of the agreed terms on liability for breach of contract in the framework agreement on the relevant transaction63s
Please independent financial advisors on the above issues to issue a special opinion, please company by May 25, 2016 to reply and disclose63s
In accordance with the requirements of the Shanghai Stock Exchange, the company will respond to the above-mentioned problems and disclose to the public, in accordance with the procedures to the Shanghai Stock Exchange to apply for the resumption of the company's shares63s
　　The Information Disclosure Media designated by the Company is the Shanghai Securities News and the Shanghai Stock Exchange website ( All information of the Company is based on the information published in the above-mentioned designated newspapers and websites, please pay attention to the company announcement, pay attention to investment risks 63s
　　This announcement is hereby made 63s
　　The Board of Directors of Meihua Biotech Group Co., Ltd 63s May 24, 2016 63s On the afternoon of May 24, 2016, Meihua Biotech Group Co., Ltd (the "Company") received a letter of inquiry from the Shanghai Stock Exchange listed company to the shanghai stock exchange on matters relating to the termination of the planning of the issuance of shares to purchase assets (SSE No 63s
　　The full text of the letter reads as follows: 63s On December 24, 2015, your company suspended trading to announce the planning of the issuance of shares to purchase assets ("this reorganization") On May 24, 2016, your company announced that it had terminated this reorganization because it had failed to reach agreement with the counterparty on such matters as competition, performance commitment, etc The restructuring is planning a suspension of trading time of up to 5 months, the investor's trading rights have a greater impact The Company is requested to supplement the verification of the following matters and to make public disclosure: 63s , the relevant rules of the listed company's material asset restructuring, such as inter-industry competition, performance commitment compensation and other issues have clear 63s Please indicate the reasons why, after a long suspension of trading, no agreement has been reached with the counterparty on the above issues, and whether the financial advisor has fulfilled the relevant reminder obligations in a diligent and responsible nature 63s
　　2 The company plans to suspend trading for this reorganization for up to 5 months, during which the suspension of trading for overseas acquisitions and other complex reasons repeatedly applied for extension of the re-listing, but the relevant restructuring progress announcement never revealed the above-mentioned risk stakes that may lead to the termination of the reorganization, please the company in conjunction with the reorganization transaction process memorandum, explain the failure to disclose the above-mentioned restructuring may be able to terminate the risk of reason 63s
　　3 According to the announcement, the company and its controlling shareholders reserve the right to pursue the legal liability of The first sugar of Hijie 63s
　　Please specify the measures that the company intends to take to safeguard its legitimate rights and interests in the context of the agreed terms on liability for breach of contract in the framework agreement on the relevant transaction 63s
　　Please independent financial advisors on the above issues to issue a special opinion, please company by May 25, 2016 to reply and disclose 63s
　　In accordance with the requirements of the Shanghai Stock Exchange, the company will respond to the above-mentioned problems and disclose to the public, in accordance with the procedures to the Shanghai Stock Exchange to apply for the resumption of the company's shares 63s
　　The Information Disclosure Media designated by the Company is the Shanghai Securities News and the Shanghai Stock Exchange website ( All information of the Company is based on the information published in the above-mentioned designated newspapers and websites, please pay attention to the company announcement, pay attention to investment risks 63s
　　This announcement is hereby made 63s
　　The Board of Directors of Meihua Biotech Group Co., Ltd 63s may 63s to share on the feed